Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 4/2013

01-07-2013 | Review

Lung cancer stem cells: a biological and clinical perspective

Authors: Ana Koren, Helena Motaln, Tanja Cufer

Published in: Cellular Oncology | Issue 4/2013

Login to get access

Abstract

Introduction

Lung cancer is the most lethal form of cancer in the world and despite significant therapeutic improvements that have been made, its survival rate still remains low. The latter is mainly due to the acquisition of resistance to systemic treatment regimens which, in turn, may be due to the presence of cancer stem cells (CSCs) within the primary tumors. CSCs constitute a subpopulation of cells that are highly tumorigenic and that exhibit biological properties similar to those of normal tissue stem cells, including an unlimited self-renewal capacity, an extensive proliferative capacity and a capacity to generate differentiated progeny. A better understanding of the signaling pathways that regulate lung CSC maintenance, proliferation, and tumorigenicity could thus lead to the design of improved approaches to lung cancer treatment.

Aim

In this review we will discuss the current knowledge on lung CSCs, their biological properties and their putative clinical relevance. By employing currently available data, we will evaluate the prognostic value of several lung CSC markers. In addition, we will discuss the release of CSCs from tumor tissue into the blood circulation via epithelial-mesenchymal transition (EMT) as an important step towards acquiring a metastatic phenotype. Finally, we will provide an outlook into novel CSC-targeting approaches for achieving less invasive diagnostic procedures and improving long-term therapeutic options.

Conclusion

Lung CSC research has gained considerable momentum to both basic and clinical applications, both aiming to identify a reliable panel of markers for lung CSCs and to clarify their function, with the final goal to develop a CSC-targeted therapy that will result in the complete elimination of CSCs for achieving significantly better long-time survival of lung cancer patients.
Literature
1.
2.
T. Cufer, T. Ovcaricek, M.E.R. O’Brien, Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur. J. Cancer 49, 1216–1225 (2012)PubMedCrossRef
3.
L.G. Collins, C. Haines, R. Perkel, R.E. Enck, Lung cancer: diagnosis, staging, and management. Am. Fam. Physician 75, 56–63 (2007)PubMed
4.
5.
A. Giangreco, K.R. Groot, S.M. Janes, Lung cancer and lung stem cells - Strange bedfellows? Am. J. Respir. Crit. Care Med. 175, 547–553 (2007)PubMedCrossRef
6.
T. Reya, S.J. Morrison, M.F. Clarke, I.L. Weissman, Stem cells, cancer, and cancer stem cells. Nature. 414, 105–111 (2001)
7.
C.F.B. Kim, E.L. Jackson, A.E. Woolfenden, S. Lawrence, I. Babar, S. Vogel et al., Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823–835 (2005)PubMedCrossRef
8.
W. Liu, N. You, N. Zhang, H. Yan, T. Wang, Z. Huang et al., Interpretation of interlocking key issues of cancer stem cells in malignant solid tumors. Cell. Oncol. 35, 397–409 (2012)CrossRef
9.
R. Pardal, M.F. Clarke, S.J. Morrison, Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 3, 895–902 (2003)PubMedCrossRef
10.
J.P. Sullivan, J.D. Minna, J.W. Shay, Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev. 29, 61–72 (2010)PubMedCrossRef
11.
M.M. Gottesman, T. Fojo, S.E. Bates, Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48–58 (2002)PubMedCrossRef
12.
L. Knez, M. Košnik, T. Ovčariček, A. Sadikov, E. Sodja, I. Kern et al., Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy. J. Cancer Res. Clin. Oncol. 138, 1551–1560 (2012)PubMedCrossRef
13.
S. Bao, Q. Wu, R.E. McLendon, Y. Hao, Q. Shi, A.B.. Hjelmeland et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006)
14.
J.L. Dembinski, S. Krauss, Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin. Exp. Metastasis 26, 611–623 (2009)PubMedCrossRef
15.
J.E. Visvader, G.J. Lindeman, Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755–768 (2008)PubMedCrossRef
16.
T. Lapidot, C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres-Cortes et al., A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 367, 645–648 (1994)PubMedCrossRef
17.
D. Bonnet, J.E. Dick, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737 (1997)PubMedCrossRef
18.
D. Ponti, A. Costa, N. Zaffaroni, G. Pratesi, G. Petrangolini, D. Coradini et al., Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65, 5506–5511 (2005)PubMedCrossRef
19.
S.K. Singh, I.D. Clarke, M. Terasaki, V.E. Bonn, C. Hawkins, J. Squire et al., Identification of a cancer stem cell in human brain. Cancer Res. 63, 5821–5828 (2003)PubMed
20.
A. Eramo, F. Lotti, G. Sette, E. Pilozzi, M. Biffoni, A. Di Virgilio et al., Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15, 504–514 (2008)PubMedCrossRef
21.
A.T. Collins, P.A. Berry, C. Hyde, M.J. Stower, N.J. Maitland, Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946–10951 (2005)PubMedCrossRef
22.
L. Ricci-Vitiani, D.G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, C. Peschle et al., Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111–115 (2007)PubMedCrossRef
23.
24.
25.
S. Zhou, J.D. Schuetz, K.D. Bunting, A.M. Colapietro, J. Sampath, J.J. Morris et al., The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7, 1028–1034 (2001)PubMedCrossRef
26.
27.
B. Jackson, C. Brocker, D.C. Thompson, W. Black, K. Vasiliou, D.W. Nebert et al., Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum. Genomics 5, 283–303 (2011)PubMedCrossRef
28.
R. Stern, Association between cancer and “acid mucopolysaccharides”: an old concept comes of age, finally. Semin. Cancer Biol. 18, 238–243 (2008)PubMedCrossRef
29.
M.M. Ho, A.V. Ng, S. Lam, J.Y. Hung, Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67, 4827–4833 (2007)PubMedCrossRef
30.
C.D. Salcido, A. Larochelle, B.J. Taylor, C.E. Dunbar, L. Varticovski, Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br. J. Cancer 102, 1636–1644 (2010)PubMedCrossRef
31.
V. Levina, A.M. Marrangoni, R. DeMarco, E. Gorelik, A.E. Lokshin, Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3, e3077 (2008)PubMedCrossRef
32.
Y.-P. Liu, C.-J. Yang, M.-S. Huang, C.-T. Yeh, A.T.H. Wu, Y.-C. Lee et al., Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res. 73, 406–416 (2013)PubMedCrossRef
33.
K. Shien, S. Toyooka, H. Yamamoto, J. Soh, M. Jida, K.L. Thu et al., Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 73, 3051–3061 (2013)PubMedCrossRef
34.
G. Bertolini, L. Roz, P. Perego, M. Tortoreto, E. Fontanella, L. Gatti et al., Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. 106, 16281–16286 (2009)PubMedCrossRef
35.
W. Hilbe, CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J. Clin. Pathol. 57, 965–969 (2004)PubMedCrossRef
36.
Y.-C. Chen, H.-S. Hsu, Y.-W. Chen, T.-H. Tsai, C.-K. How, C.-Y. Wang et al., Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 3, e2637 (2008)PubMedCrossRef
37.
J.S. Moreb, J.R. Zucali, B. Ostmark, N.A. Benson, Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by Aldefluor flow cytometry-based assay. Cytometry B Clin. Cytom. 289, 281–289 (2007)
38.
F. Jiang, Q. Qiu, A. Khanna, N.W. Todd, J. Deepak, L. Xing et al., Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 7, 330–338 (2009)PubMedCrossRef
39.
D. Ucar, C.R. Cogle, J.R. Zucali, B. Ostmark, E.W. Scott, R. Zori et al., Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem. Biol. Interact. 178, 48–55 (2009)PubMedCrossRef
40.
J.P. Sullivan, M. Spinola, M. Dodge, M.G. Raso, C. Behrens, B. Gao et al., Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 70, 9937–9948 (2010)PubMedCrossRef
41.
E.L.-H. Leung, R.R. Fiscus, J.W. Tung, V.P.-C. Tin, L.C. Cheng, A.D.-L. Sihoe et al., Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 5, e14062 (2010)PubMedCrossRef
42.
S. Akunuru, Q. James Zhai, Y. Zheng, Non-small cell lung cancer stem/ progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity. Cell Death Dis. 3, e352 (2012)PubMedCrossRef
43.
X. Meng, X. Wang, Y. Wang, More than 45 % of A549 and H446 cells are cancer initiating cells: evidence from cloning and tumorigenic analyses. Oncol. Rep. 21, 995–1000 (2009)PubMed
44.
G.P. Kalemkerian, Advances in the treatment of small-cell lung cancer. Semin. Respir. Crit. Care Med. 32, 94–101 (2011)PubMedCrossRef
45.
K. Hotta, K. Kiura, Y. Fujiwara, N. Takigawa, I. Oze, N. Ochi et al., Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer. Ann. Oncol. 20, 829–834 (2009)PubMedCrossRef
46.
Z.A. Rasheed, J. Kowalski, B.D. Smith, W. Matsui, Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells 29, 883–887 (2011)PubMedCrossRef
47.
W.C.-S. Cho, Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed. Pharmacother. 61, 515–519 (2007)PubMedCrossRef
48.
J.A. Ludwig, J.N. Weinstein, Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5, 845–856 (2005)PubMedCrossRef
49.
A.V. Salnikov, J. Gladkich, G. Moldenhauer, M. Volm, J. Mattern, I. Herr, CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int. J. Cancer 126, 950–958 (2010)PubMed
50.
T. Woo, K. Okudela, H. Mitsui, T. Yazawa, N. Ogawa, M. Tajiri et al., Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int. J. Clin. Exp. Pathol. 4, 32–42 (2010)PubMed
51.
Li, H. Zeng, K. Ying, The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med. Oncol. 28, 1458–1462 (2011)PubMedCrossRef
52.
E. Herpel, K. Jensen, T. Muley, A. Warth, P.A. Schnabel, M. Meister et al., The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer. Anticancer. Res. 31, 4491–4500 (2011)PubMed
53.
K. Vrzalikova, J. Skarda, J. Ehrmann, P.G. Murray, E. Fridman, J. Kopolovic et al., Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J. Cancer Res. Clin. Oncol. 134, 1037–1042 (2008)PubMedCrossRef
54.
J. Kikuchi, I. Kinoshita, Y. Shimizu, E. Kikuchi, J. Konishi, S. Oizumi et al., Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 116, 3015–3024 (2010)PubMedCrossRef
55.
K. Shien, S. Toyooka, K. Ichimura, J. Soh, M. Furukawa, Y. Maki et al., Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer 7, 162–167 (2012)CrossRef
56.
P. Micke, M. Basrai, A. Faldum, F. Bittinger, L. Rönnstrand, A. Blaukat et al., Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin. Cancer Res. 9, 188–194 (2003)PubMed
57.
X. Zhang, B. Han, J. Huang, B. Zheng, Q. Geng, F. Aziz et al., Prognostic significance of OCT4 expression in adenocarcinoma of the lung. Jpn. J. Clin. Oncol. 40, 961–966 (2010)PubMedCrossRef
58.
X. Li, J. Wang, Z. Xu, A. Ahmad, E. Li, Y. Wang et al., Expression of sox2 and oct4 and their clinical significance in human non-small-cell lung cancer. Int. J. Mol. Sci. 13, 7663–7675 (2012)PubMedCrossRef
59.
L. Cortes-Dericks, D. Galetta, L. Spaggiari, R.A. Schmid, G. Karoubi, High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals. Eur. J. Cardiothorac. Surg. 41, e173–e181 (2012)PubMedCrossRef
60.
F. Zeppernick, R. Ahmadi, B. Campos, C. Dictus, B.M. Helmke, N. Becker et al., Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14, 123–129 (2008)PubMedCrossRef
61.
W. Song, H. Li, K. Tao, R. Li, Z. Song, Q. Zhao et al., Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int. J. Clin. Pract. 62, 1212–1218 (2008)PubMedCrossRef
62.
T. Li, Y. Su, Y. Mei, Q. Leng, B. Leng, Z. Liu et al., ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients’ outcome. Lab Investig. 90, 234–244 (2010)PubMedCrossRef
63.
C. Ginestier, M.H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown et al., ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555–567 (2007)PubMedCrossRef
64.
B. Chang, G. Liu, F. Xue, D.G. Rosen, L. Xiao, X. Wang et al., ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod. Pathol. 22, 817–823 (2009)PubMed
65.
C. Tempfer, A. Lösch, H. Heinzl, G. Häusler, E. Hanzal, H. Kölbl et al., Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer. Eur. J. Cancer 32A, 2023–2025 (1996)PubMedCrossRef
66.
K.-C. Wei, C.-Y. Huang, P.-Y. Chen, L.-Y. Feng, T.-W.E. Wu, S.-M. Chen et al., Evaluation of the prognostic value of CD44 in glioblastoma multiforme. Anticancer. Res. 30, 253–259 (2010)PubMed
67.
J.S. Dovey, S.J. Zacharek, C.F. Kim, J.A. Lees, Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc. Natl. Acad. Sci. 105, 11857–11862 (2008)PubMedCrossRef
68.
K. Wu, Direct activation of Bmi1 by Twist1: implications in cancer stemness, epithelial-mesenchymal transition, and clinical significance. Chang Gung Med. J. 34, 229–238 (2011)PubMed
69.
H. Wang, K. Pan, H. Zhang, D. Weng, J. Zhou, J. Li et al., Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 134, 535–541 (2008)PubMedCrossRef
70.
J.-H. Liu, L.-B. Song, X. Zhang, B.-H. Guo, Y. Feng, X.-X. Li et al., Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J. Surg. Oncol. 97, 267–272 (2008)PubMedCrossRef
71.
Y.J. Choi, Y. La Choi, E.Y. Cho, Y.K. Shin, K.W. Sung, Y.K. Hwang et al., Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Res. Treat. 113, 83–93 (2009)PubMedCrossRef
72.
K. Takahashi, K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda et al., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007)PubMedCrossRef
73.
M. Field, A. Alvarez, S. Bushnev, K. Sugaya, Embryonic stem cell markers distinguishing cancer stem cells from normal human neuronal stem cell populations in malignant glioma patients. Clin. Neurosurg. 57, 151–159 (2010)PubMed
74.
S.-H. Chiou, M.-L. Wang, Y.-T. Chou, C.-J. Chen, C.-F. Hong, W.-J. Hsieh et al., Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 70, 10433–10444 (2010)PubMedCrossRef
75.
J. Taipale, P.A. Beachy, The Hedgehog and Wnt signalling pathways in cancer. Nature 411, 349–354 (2001)PubMedCrossRef
76.
P. Polakis, Wnt signaling and cancer Wnt signaling and cancer. Genes Dev. 14, 1837–1851 (2000)PubMed
77.
L. Jiang, J. Li, L. Song, Bmi-1, stem cells and cancer. Acta Biochim. Biophys. Sin. (Shanghai) 41, 527–534 (2009)CrossRef
78.
M.R. García Campelo, G. Alonso Curbera, G. Aparicio Gallego, E. Grande Pulido, L.M. Antón Aparicio, Stem cell and lung cancer development: blaming the Wnt, Hh and Notch signalling pathway. Clin. Transl. Oncol. 13, 77–83 (2011)PubMedCrossRef
79.
J. Vestergaard, M.W. Pedersen, N. Pedersen, C. Ensinger, Z. Tümer, N. Tommerup et al., Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. Lung Cancer 52, 281–290 (2006)PubMedCrossRef
80.
D.N. Watkins, D.M. Berman, S.G. Burkholder, B. Wang, P.A. Beachy, S.B. Baylin, Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422, 313–317 (2003)PubMedCrossRef
81.
L. You, B. He, Z. Xu, K. Uematsu, J. Mazieres, I. Mikami et al., Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 23, 6170–6174 (2004)PubMedCrossRef
82.
V. Levina, A. Marrangoni, T. Wang, S. Parikh, Y. Su, R. Herberman et al., Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res. 70, 338–346 (2010)PubMedCrossRef
83.
T. Hu, S. Liu, D.R. Breiter, F. Wang, Y. Tang, S. Sun, Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res. 68, 6533–6540 (2008)PubMedCrossRef
84.
A. Eramo, T.L. Haas, R. De Maria, Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene 29, 4625–4635 (2010)PubMedCrossRef
85.
R.J. Kelly, D. Draper, C.C. Chen, R.W. Robey, W.D. Figg, R.L. Piekarz et al., A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin. Cancer Res. 17, 569–580 (2011)PubMedCrossRef
86.
A. Singh, J. Settleman, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741–4751 (2010)PubMedCrossRef
87.
J.P. Thiery, J.P. Sleeman, Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7, 131–142 (2006)PubMedCrossRef
88.
M. Guarino, B. Rubino, G. Ballabio, The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39, 305–318 (2008)CrossRef
89.
J.P. Thiery, H. Acloque, R.Y.J. Huang, M.A. Nieto, Epithelial-mesenchymal transitions in development and disease. Cell 139, 871–890 (2009)PubMedCrossRef
90.
J. Thiery, Epithelial–mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 15, 740–746 (2003)PubMedCrossRef
91.
S.A. Mani, W. Guo, M.-J. Liao, E.N. Eaton, A. Ayyanan, A.Y. Zhou et al., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008)PubMedCrossRef
92.
A.-P. Morel, M. Lièvre, C. Thomas, G. Hinkal, S. Ansieau, A. Puisieux, Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3, e2888 (2008)PubMedCrossRef
93.
V.L. Battula, K.W. Evans, B.G. Hollier, Y. Shi, F.C. Marini, A. Ayyanan et al., Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 28, 1435–1445 (2010)PubMedCrossRef
94.
J.K. Rho, Y.J. Choi, J.K. Lee, B.-Y. Ryoo, I. Il Na, S.H. Yang et al., Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63, 219–226 (2009)PubMedCrossRef
95.
K. Suda, K. Tomizawa, M. Fujii, H. Murakami, H. Osada, Y. Maehara et al., Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J. Thorac. Oncol. 6, 1152–1161 (2011)PubMedCrossRef
96.
F. Nurwidya, F. Takahashi, A. Murakami, K. Takahashi, Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res. Treat. 44, 151–156 (2012)PubMedCrossRef
97.
T. Ashworth, A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust. Med. J. 14, 146–147 (1869)
98.
W.J. Allard, J. Matera, M.C. Miller, M. Repollet, M.C. Connelly, C. Rao et al., Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10, 6897–6904 (2004)PubMedCrossRef
99.
M. Alunni-Fabbroni, M.T. Sandri, Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods 50, 289–297 (2010)PubMedCrossRef
100.
B. Kubuschok, B. Passlick, J.R. Izbicki, O. Thetter, K. Pantel, Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J. Clin. Oncol. 17, 19–24 (1999)PubMed
101.
T.J.N. Hiltermann, M.M. Pore, A. Van Den Berg, W. Timens, H.M. Boezen, J.J.W. Liesker et al., Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann. Oncol. 23, 2937–2942 (2012)PubMedCrossRef
102.
V. Hofman, M.I. Ilie, E. Long, E. Selva, C. Bonnetaud, T. Molina et al., Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the Cell Search AssayTM and the isolation by size of epithelial tumor cell method. Int. J. Cancer 129, 1651–1660 (2011)PubMedCrossRef
103.
V. Hofman, C. Bonnetaud, M.I. Ilie, P. Vielh, J.M. Vignaud, J.F. Fléjou et al., Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin. Cancer Res. 17, 827–835 (2011)PubMedCrossRef
104.
M.G. Krebs, J.-M. Hou, R. Sloane, L. Lancashire, L. Priest, D. Nonaka et al., Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J. Thorac. Oncol. 7, 306–315 (2011)CrossRef
105.
A. Rolle, R. Günzel, U. Pachmann, B. Willen, K. Höffken, K. Pachmann, Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(R) is a predictor for relapse: a preliminary report. World J. Surg. Oncol. 3, 18 (2005)PubMedCrossRef
106.
Y.-F. Sun, X.-R. Yang, J. Zhou, S.-J. Qiu, J. Fan, Y. Xu, Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J. Cancer Res. Clin. Oncol. 137, 1151–1173 (2011)PubMedCrossRef
107.
M. Yu, A. Bardia, B.S. Wittner, S.L. Stott, M.E. Smas, D.T. Ting et al., Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580–584 (2013)PubMedCrossRef
108.
A. Gradilone, C. Raimondi, C. Nicolazzo, A. Petracca, O. Gandini, B. Vincenzi et al., Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J. Cell Mol. Med. 15, 1066–1070 (2011)PubMedCrossRef
109.
M. Balic, H. Lin, L. Young, D. Hawes, A. Giuliano, G. McNamara et al., Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12, 5615–5621 (2006)PubMedCrossRef
110.
Z.F. Yang, P. Ngai, D.W. Ho, W.C. Yu, M.N.P. Ng, C.K. Lau et al., Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 47, 919–928 (2008)PubMedCrossRef
111.
P.A. Theodoropoulos, H. Polioudaki, S. Agelaki, G. Kallergi, Z. Saridaki, D. Mavroudis et al., Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 288, 99–106 (2010)PubMedCrossRef
112.
N. Mehra, M. Penning, J. Maas, L.V. Beerepoot, N. van Daal, C.H. van Gils et al., Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin. Cancer Res. 12, 4859–4866 (2006)PubMedCrossRef
113.
T. Brabletz, A. Jung, S. Spaderna, F. Hlubek, T. Kirchner, Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 5, 744–749 (2005)PubMedCrossRef
Metadata
Title
Lung cancer stem cells: a biological and clinical perspective
Authors
Ana Koren
Helena Motaln
Tanja Cufer
Publication date
01-07-2013
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 4/2013
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-013-0141-9

Other articles of this Issue 4/2013

Cellular Oncology 4/2013 Go to the issue

Original Paper

Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas

Original Paper

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer

Original Paper

Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor

OriginalPaper

Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: paving the way for molecular imaging

Original Paper

Biofunctional characteristics of in situ and invasive breast carcinoma

Original Paper

In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits